Theravance Biopharma (TBPH) EBITDA (2013 - 2026)
Theravance Biopharma (TBPH) posted quarterly EBITDA of -$9.5 million for Q1 2026, up 34.3% year-over-year from -$7.1 million in Q1 2025, and down 147.39% quarter-over-quarter from $20.0 million in Q4 2025.
Theravance Biopharma (TBPH) EBITDA (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported EBITDA for 14 consecutive years, with -$9.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA rose 34.3% year-over-year to -$9.5 million; the TTM figure through Mar 2026 stood at $1.3 million (up 102.69% YoY), while the FY2025 annual figure was -$3.6 million, up 92.33% from the prior year.
- EBITDA declined to -$9.5 million in Q1 2026 per TBPH's latest filing, from $20.0 million in the prior quarter.
- Across five years, EBITDA topped out at $20.0 million in Q4 2025 and bottomed at -$38.5 million in Q1 2022.
- Historically, EBITDA has averaged -$12.2 million across 5 years, with a median of -$10.8 million in 2024.
- Annual changes were most pronounced in 2024 — EBITDA plunged 47.44% — and 2025, when it surged 317.52%.
- Theravance Biopharma's EBITDA stood at -$17.4 million in 2022, then surged by 64.2% to -$6.2 million in 2023, then plunged by 47.44% to -$9.2 million in 2024, then soared by 317.52% to $20.0 million in 2025, then sank by 147.39% to -$9.5 million in 2026.
- Business Quant data shows TBPH's EBITDA at -$9.5 million in Q1 2026, $20.0 million in Q4 2025, and -$6.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | -8.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.28 Mn |
| Mar 31, 2026 | -9.48 Mn |
| Dec 31, 2025 | 20.01 Mn |
| Sep 30, 2025 | -6.46 Mn |
| Jun 30, 2025 | -2.73 Mn |
| Mar 31, 2025 | -14.43 Mn |
| Dec 31, 2024 | -9.20 Mn |
| Sep 30, 2024 | -10.84 Mn |
| Jun 30, 2024 | -15.71 Mn |
| Mar 31, 2024 | -11.21 Mn |
| Dec 31, 2023 | -6.24 Mn |
| Sep 30, 2023 | -8.76 Mn |
| Jun 30, 2023 | -16.12 Mn |
| Mar 31, 2023 | -24.91 Mn |
| Dec 31, 2022 | -17.43 Mn |
| Sep 30, 2022 | -9.14 Mn |
| Jun 30, 2022 | -26.88 Mn |
| Mar 31, 2022 | -38.50 Mn |
| Dec 31, 2021 | -56.17 Mn |
| Sep 30, 2021 | -53.62 Mn |